HSP90AA1 and cancer: Numerous Hsp90 client proteins are often mutated or overexpressed in several types of human cancer, including NSCLC2,53, and these proteins mediate cancer cell proliferation, survival, angiogenesis, invasion, metastasis, and resistance to conventional or targeted anticancer drugs, such as erlotinib, trastuzumab, paclitaxel, and cisplatin1,2,54–57.